1. Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study. (18th January 2013) Authors: Papp, K.A.; Langley, R.G.; Sigurgeirsson, B.; Abe, M.; Baker, D.R.; Konno, P.; Haemmerle, S.; Thurston, H.J.; Papavassilis, C.; Richards, H.B. Journal: British journal of dermatology Issue: Volume 168:Number 2(2013:Feb.) Page Start: 412 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY. (2nd June 2020) Authors: Braun, J.; Blanco, R.; Dokoupilova, E.; Gensler, L. S.; Kivitz, A.; Hall, S.; Kameda, H.; Poddubnyy, D.; Van de Sande, M.; Van der Heijde, D.; Wiksten, A.; Porter, B.; Richards, H.; Haemmerle, S.; Deodhar, A. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study. (13th December 2013) Authors: Sigurgeirsson, B.; Kircik, L.; Nemoto, O.; Mikazans, I.; Haemmerle, S.; Thurston, H.J.; Papavassilis, C.; Richards, H.B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 8(2014:Aug.) Page Start: 1127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗